Compounds > prednisolone
Page last updated: 2024-11-06

prednisolone and Muscular Dystrophy

prednisolone has been researched along with Muscular Dystrophy in 25 studies

Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.

Research Excerpts

ExcerptRelevanceReference
"We conducted a double blind controlled trial in 28 Duchenne muscular dystrophy (DMD) patients with Deflazacort (DF), an oxazoline derivative of prednisolone which reduces its side-effects."9.07Steroids in Duchenne muscular dystrophy--deflazacort trial. ( Corderi, J; Dubrovsky, AL; Flores, D; Marco, P; Mesa, LE, 1991)
"Seven patients, aged 10-17 years, with Duchenne muscular dystrophy were treated orally with prednisolone (PSL) at a dose of 0."7.68Decrease in urinary excretion of 3-methylhistidine by patients with Duchenne muscular dystrophy during glucocorticoid treatment. ( Adachi, K; Inui, T; Kawai, H; Kimura, C; Nishida, Y; Saito, S, 1993)
"The effects of diethylstilbestrol (DES) and prednisolone (Pr), administered alone or in combination, on the serum enzyme activities in Duchenne's muscular dystrophy (DMD) have been evaluated."7.65Effects of the simultaneous administration of diethylstilbestrol and prednisolone on serum enzymes in Duchenne's muscular dystrophy. ( Bozyk, ME; Cohen, L; Morgan, J, 1977)
"A special program for long-term application of low-dose prednisolone treatment in Duchenne-Becker muscular dystrophy with complex control of the patients' state was developed."5.09[The use of low doses of prednisolone for the treatment of patients with Duchenne-Becker myodystrophy]. ( Gerasimova, NL; Krakhmaleva, IN; Lunga, IN; Rodnikova, NI; Shakhovskaia, NI; Shakhovskiĭ, VA; Shishkin, SS; Skozobtseva, LF; Tarksh, MA, 1999)
"We conducted a double blind controlled trial in 28 Duchenne muscular dystrophy (DMD) patients with Deflazacort (DF), an oxazoline derivative of prednisolone which reduces its side-effects."5.07Steroids in Duchenne muscular dystrophy--deflazacort trial. ( Corderi, J; Dubrovsky, AL; Flores, D; Marco, P; Mesa, LE, 1991)
"Seven patients, aged 10-17 years, with Duchenne muscular dystrophy were treated orally with prednisolone (PSL) at a dose of 0."3.68Decrease in urinary excretion of 3-methylhistidine by patients with Duchenne muscular dystrophy during glucocorticoid treatment. ( Adachi, K; Inui, T; Kawai, H; Kimura, C; Nishida, Y; Saito, S, 1993)
" The ratio of 3-methylhistidine:creatinine excretion, a measure of the fractional catabolic rate of myofibrillar protein was increased in severe injury, thyrotoxicosis, neoplastic disease, prednisolone administration, and sometimes Duchenne muscular dystrophy."3.66Clinical usefulness of urinary 3-methylhistidine excretion in indicating muscle protein breakdown. ( Bacon, S; Carter, A; Elia, M; Smith, R; Winearls, CG, 1981)
"The effects of diethylstilbestrol (DES) and prednisolone (Pr), administered alone or in combination, on the serum enzyme activities in Duchenne's muscular dystrophy (DMD) have been evaluated."3.65Effects of the simultaneous administration of diethylstilbestrol and prednisolone on serum enzymes in Duchenne's muscular dystrophy. ( Bozyk, ME; Cohen, L; Morgan, J, 1977)
"Serum creatine phosphokinase activity increased significantly four or six hours after the administration of prednisolone in patients with muscular dystrophy of various types, whereas it did not increase in other muscular disorders."3.65Response of serum creatine phosphokinase to steroid hormone. ( Matsuo, B; Oimomi, M; Shinko, T; Shutta, K; Takahashi, K, 1975)
" We also investigated the effect of glucocorticoid in 10 DMD patients taking a dosage of prednisolone 1 mg/kg on alternate day."2.68[Glucocorticoid therapy in Duchenne muscular dystrophy]. ( Kang, J, 1996)

Research

Studies (25)

TimeframeStudies, this research(%)All Research%
pre-199013 (52.00)18.7374
1990's8 (32.00)18.2507
2000's1 (4.00)29.6817
2010's3 (12.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Sreetama, SC1
Chandra, G1
Van der Meulen, JH2
Ahmad, MM1
Suzuki, P1
Bhuvanendran, S1
Nagaraju, K2
Hoffman, EP2
Jaiswal, JK2
Heier, CR1
Damsker, JM1
Yu, Q1
Dillingham, BC1
Huynh, T1
Sali, A1
Miller, BK1
Phadke, A1
Scheffer, L1
Quinn, J1
Tatem, K1
Jordan, S1
Dadgar, S1
Rodriguez, OC1
Albanese, C1
Calhoun, M1
Gordish-Dressman, H1
Connor, EM1
McCall, JM1
Reeves, EK1
Komaki, H1
Gosselin, LE1
McCormick, KM1
Cohen, L3
Morgan, J3
Babbs, R1
Karrison, TG1
Giacomoni, M1
Jörg, J1
Gerhard, H1
Elia, M1
Carter, A1
Bacon, S1
Winearls, CG1
Smith, R1
Vita, G1
Natoli, M1
Dattola, R1
Messina, C1
Bäckman, E1
Henriksson, KG1
Kawai, H1
Adachi, K1
Nishida, Y1
Inui, T1
Kimura, C1
Saito, S1
Kang, J1
Takagi, A1
Watanabe, T1
Kojima, S1
Endo, Y1
Shakhovskaia, NI1
Shishkin, SS1
Skozobtseva, LF1
Shakhovskiĭ, VA1
Rodnikova, NI1
Lunga, IN1
Tarksh, MA1
Gerasimova, NL1
Krakhmaleva, IN1
Bozyk, ME2
Takahashi, K2
Oimomi, M1
Shinko, T1
Shutta, K1
Matsuo, B1
Mesa, LE1
Dubrovsky, AL1
Corderi, J1
Marco, P1
Flores, D1
McDouall, RM1
Dunn, MJ1
Dubowitz, V1
Kinoshita, M1
Nishina, M1
Koya, N1
Siegel, IM1
Miller, JE1
Ray, RD1
Oimori, M1
Goto, T1
Tateiwa, M1
Mori, H1
Mason, DA1
Thomson, WH1
Cavalea, GG1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase II Open-Label, Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys Ages 2 to <4 Years and 7 to <18 Years With Duchenne Muscular Dystrophy (DMD)[NCT05185622]Phase 254 participants (Anticipated)Interventional2022-03-21Recruiting
A Phase II Pilot Trial of Vamorolone vs. Placebo for the Treatment of Becker Muscular Dystrophy[NCT05166109]Phase 239 participants (Anticipated)Interventional2022-07-07Recruiting
A Phase IIb Randomized, Double-blind, Parallel Group, Placebo- and Active-controlled Study With Double-Blind Extension to Assess the Efficacy and Safety of Vamorolone in Ambulant Boys With Duchenne Muscular Dystrophy (DMD)[NCT03439670]Phase 2121 participants (Actual)Interventional2018-06-29Completed
Duchenne Muscular Dystrophy: Double-blind Randomized Trial to Find Optimum Steroid Regimen[NCT01603407]Phase 3196 participants (Actual)Interventional2013-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Efficacy Measured by Time to Stand Test (TTSTAND) Velocity in Rises/Second Change From Baseline

Vamorolone at 6.0mg/kg/day vs. placebo group in change from baseline to the Week 24 assessment (NCT03439670)
Timeframe: 24 weeks

InterventionRises/Seconds (Mean)
Treatment Group 1-.007
Treatment Group 20.054

6 Minute Walk Test

Measures the total distance walked in 6 minutes averaged over all post-baseline follow-up visits through Month 36. (NCT01603407)
Timeframe: Average of Months 3, 6, 12, 18, 24, 30 and 36 visits

Interventionmeters (Least Squares Mean)
Daily Prednisone384.95
Daily Deflazacort384.17
Intermittent Prednisone346.81

Forced Vital Capacity

Forced vital capacity was measured during a spirometry test. Forced expiratory volume (FEV) measures how much air a person can exhale during a forced breath. Forced vital capacity (FVC) is the total amount of air exhaled during the FEV test. (NCT01603407)
Timeframe: Average of Months 3, 6, 12, 18, 24, 30 and 36 visits

Interventionliters (Least Squares Mean)
Daily Prednisone1.4
Daily Deflazacort1.4
Intermittent Prednisone1.5

Fractional Shortening Percent

Measured by trans-thoracic echocardiogram and 12-lead ECG. (NCT01603407)
Timeframe: 36 months

Interventionpercentage of fractional shortening (Least Squares Mean)
Daily Prednisone33.74
Daily Deflazacort34.01
Intermittent Prednisone34.33

Heart Rate

Measured by trans-thoracic echocardiogram and 12-lead ECG. (NCT01603407)
Timeframe: 36 months

Interventionbpm (Least Squares Mean)
Daily Prednisone94.10
Daily Deflazacort93.52
Intermittent Prednisone91.65

Left Ventricular Ejection Fraction Percent

Measured by trans-thoracic echocardiogram and 12-lead ECG. (NCT01603407)
Timeframe: 36 months

Interventionpercentage of ejection fraction (Least Squares Mean)
Daily Prednisone61.88
Daily Deflazacort62.65
Intermittent Prednisone62.45

North Star Ambulatory Assessment (NSAA) Score

"The North Star Ambulatory Assessment (NSAA) is a 17-item rating scale that is used to measure functional motor abilities in ambulant children with Duchenne Muscular Dystrophy (DMD). It is usually used to monitor the progression of the disease and treatment effects.~The activities are graded as follows:~2 - Normal - no obvious modification of activity~1 - Modified method but achieves goal independent of physical assistance from another 0 - Unable to achieve independently This scale is ordinal with 34 as the maximum score indicating fully-independent function." (NCT01603407)
Timeframe: Average of Months 3, 6, 12, 18, 24, 30 and 36 visits

Interventionscore on a scale (Least Squares Mean)
Daily Prednisone23.7
Daily Deflazacort24.0
Intermittent Prednisone20.7

Number of Participants Who Tolerated the Regimen

The number of participants who completed 36 months of follow-up on the originally assigned dosage (for weight) of study medication. (NCT01603407)
Timeframe: 3 years

InterventionParticipants (Count of Participants)
Daily Prednisone36
Daily Deflazacort36
Intermittent Prednisone37

Participant Body Mass Index

(NCT01603407)
Timeframe: 36 months

Interventionkilograms/square meter (Least Squares Mean)
Daily Prednisone18.9
Daily Deflazacort18.3
Intermittent Prednisone18.1

Participant Height

(NCT01603407)
Timeframe: 36 months

Interventioncentimeters (Least Squares Mean)
Daily Prednisone116.8
Daily Deflazacort115.3
Intermittent Prednisone119.9

Participant Weight

(NCT01603407)
Timeframe: 36 months

Interventionkilograms (Least Squares Mean)
Daily Prednisone26.3
Daily Deflazacort24.9
Intermittent Prednisone26.3

PR Interval

Measured by trans-thoracic echocardiogram and 12-lead ECG. (NCT01603407)
Timeframe: 36 months

Interventionmilliseconds (Least Squares Mean)
Daily Prednisone115.59
Daily Deflazacort116.87
Intermittent Prednisone117.90

Quality of Life - Parent

Quality of life was measured by parent/guardian self-report for all children utilizing the PEDSQL measurement tool. This is a 23-question tool. Scores can range from 0 to 100, with higher scores indicating better quality of life for the child. (NCT01603407)
Timeframe: Average of Months 12, 24, and 36 visits

Interventionscore on a scale (Least Squares Mean)
Daily Prednisone64.88
Daily Deflazacort63.71
Intermittent Prednisone61.33

Quality of Life- Child

Quality of life was measured by child self-report in children age 5 and older utilizing the PEDSQL measurement tool. This is a 23-question tool. Scores can range from 0 to 100, with higher scores indicating better quality of life. (NCT01603407)
Timeframe: Average of Months 12, 24, and 36 visits

Interventionscore on a scale (Least Squares Mean)
Daily Prednisone67.39
Daily Deflazacort64.96
Intermittent Prednisone65.07

Range of Motion (Goniometry) of Left Ankle

Range of motion at the ankle joint in dorsiflexion measured in degrees from plantigrade averaged over all post-baseline visits. (NCT01603407)
Timeframe: Average of Months 3, 6, 12, 18, 24, 30 and 36 visits

Interventiondegrees (Mean)
Daily Prednisone4.39
Daily Deflazacort3.29
Intermittent Prednisone2.67

Range of Motion (Goniometry) of Right Ankle

Range of motion at the ankle joint in dorsiflexion measured in degrees from plantigrade averaged over all post-baseline visits. (NCT01603407)
Timeframe: Average of Months 3, 6, 12, 18, 24, 30 and 36 visits

Interventiondegrees (Mean)
Daily Prednisone4.05
Daily Deflazacort2.81
Intermittent Prednisone2.29

Rise From the Floor Velocity

Reciprocal of time to rise from the floor (NCT01603407)
Timeframe: Average of Months 3, 6, 12, 18, 24, 30 and 36 visits

Interventionrise/sec (Least Squares Mean)
Daily Prednisone0.24
Daily Deflazacort0.24
Intermittent Prednisone0.18

Treatment Satisfaction Questionnaire for Medication (TSQM) Global Satisfaction With Treatment Score

The TSQM Global Satisfaction with Treatment is a 14-item questionnaire that ranges from 0 - 100 with higher scores indicating better outcomes. (NCT01603407)
Timeframe: Average of Months 3, 6, 12, 18, 24, 30 and 36 visits

Interventionscore on a scale (Least Squares Mean)
Daily Prednisone71.2
Daily Deflazacort67.8
Intermittent Prednisone65.1

Reviews

2 reviews available for prednisolone and Muscular Dystrophy

ArticleYear
[Current status and future prospect of the therapy for muscular dystrophy].
    No to hattatsu = Brain and development, 2014, Volume: 46, Issue:2

    Topics: Clinical Trials as Topic; Comprehensive Health Care; Drug Discovery; Exons; Genetic Therapy; Humans;

2014
Targeting the immune system to improve ventilatory function in muscular dystrophy.
    Medicine and science in sports and exercise, 2004, Volume: 36, Issue:1

    Topics: Animals; Anti-Inflammatory Agents; Collagen; Diaphragm; Disease Models, Animal; Humans; Inflammation

2004

Trials

5 trials available for prednisolone and Muscular Dystrophy

ArticleYear
Low-dose prednisolone treatment in Duchenne and Becker muscular dystrophy.
    Neuromuscular disorders : NMD, 1995, Volume: 5, Issue:3

    Topics: Adolescent; Adult; Child; Child, Preschool; Double-Blind Method; Humans; Male; Muscles; Muscular Dys

1995
[Glucocorticoid therapy in Duchenne muscular dystrophy].
    Rinsho shinkeigaku = Clinical neurology, 1996, Volume: 36, Issue:12

    Topics: Double-Blind Method; Humans; Muscular Dystrophies; Prednisolone

1996
[The use of low doses of prednisolone for the treatment of patients with Duchenne-Becker myodystrophy].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 1999, Volume: 99, Issue:6

    Topics: Adolescent; Adult; Child; Child, Preschool; Double-Blind Method; Electromyography; Glucocorticoids;

1999
Steroids in Duchenne muscular dystrophy--deflazacort trial.
    Neuromuscular disorders : NMD, 1991, Volume: 1, Issue:4

    Topics: Anti-Inflammatory Agents; Child; Child, Preschool; Double-Blind Method; Humans; Muscular Dystrophies

1991
Failure of corticosteroid in the treatment of Duchenne (pseudo-hypertrophic) muscular dystrophy. Report of a clinically matched three year double-blind study.
    IMJ. Illinois medical journal, 1974, Volume: 145, Issue:1

    Topics: Child; Clinical Trials as Topic; Humans; Male; Muscular Dystrophies; Placebos; Prednisolone

1974

Other Studies

18 other studies available for prednisolone and Muscular Dystrophy

ArticleYear
Membrane Stabilization by Modified Steroid Offers a Potential Therapy for Muscular Dystrophy Due to Dysferlin Deficit.
    Molecular therapy : the journal of the American Society of Gene Therapy, 2018, 09-05, Volume: 26, Issue:9

    Topics: Adolescent; Animals; Cells, Cultured; Dysferlin; Humans; Male; Mice; Muscular Dystrophies; Myoblasts

2018
Membrane Stabilization by Modified Steroid Offers a Potential Therapy for Muscular Dystrophy Due to Dysferlin Deficit.
    Molecular therapy : the journal of the American Society of Gene Therapy, 2018, 09-05, Volume: 26, Issue:9

    Topics: Adolescent; Animals; Cells, Cultured; Dysferlin; Humans; Male; Mice; Muscular Dystrophies; Myoblasts

2018
Membrane Stabilization by Modified Steroid Offers a Potential Therapy for Muscular Dystrophy Due to Dysferlin Deficit.
    Molecular therapy : the journal of the American Society of Gene Therapy, 2018, 09-05, Volume: 26, Issue:9

    Topics: Adolescent; Animals; Cells, Cultured; Dysferlin; Humans; Male; Mice; Muscular Dystrophies; Myoblasts

2018
Membrane Stabilization by Modified Steroid Offers a Potential Therapy for Muscular Dystrophy Due to Dysferlin Deficit.
    Molecular therapy : the journal of the American Society of Gene Therapy, 2018, 09-05, Volume: 26, Issue:9

    Topics: Adolescent; Animals; Cells, Cultured; Dysferlin; Humans; Male; Mice; Muscular Dystrophies; Myoblasts

2018
VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects.
    EMBO molecular medicine, 2013, Volume: 5, Issue:10

    Topics: Animals; Anti-Inflammatory Agents; Cell Line; Cell Membrane; Immunosuppressive Agents; Lasers; Mice;

2013
VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects.
    EMBO molecular medicine, 2013, Volume: 5, Issue:10

    Topics: Animals; Anti-Inflammatory Agents; Cell Line; Cell Membrane; Immunosuppressive Agents; Lasers; Mice;

2013
VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects.
    EMBO molecular medicine, 2013, Volume: 5, Issue:10

    Topics: Animals; Anti-Inflammatory Agents; Cell Line; Cell Membrane; Immunosuppressive Agents; Lasers; Mice;

2013
VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects.
    EMBO molecular medicine, 2013, Volume: 5, Issue:10

    Topics: Animals; Anti-Inflammatory Agents; Cell Line; Cell Membrane; Immunosuppressive Agents; Lasers; Mice;

2013
VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects.
    EMBO molecular medicine, 2013, Volume: 5, Issue:10

    Topics: Animals; Anti-Inflammatory Agents; Cell Line; Cell Membrane; Immunosuppressive Agents; Lasers; Mice;

2013
VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects.
    EMBO molecular medicine, 2013, Volume: 5, Issue:10

    Topics: Animals; Anti-Inflammatory Agents; Cell Line; Cell Membrane; Immunosuppressive Agents; Lasers; Mice;

2013
VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects.
    EMBO molecular medicine, 2013, Volume: 5, Issue:10

    Topics: Animals; Anti-Inflammatory Agents; Cell Line; Cell Membrane; Immunosuppressive Agents; Lasers; Mice;

2013
VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects.
    EMBO molecular medicine, 2013, Volume: 5, Issue:10

    Topics: Animals; Anti-Inflammatory Agents; Cell Line; Cell Membrane; Immunosuppressive Agents; Lasers; Mice;

2013
VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects.
    EMBO molecular medicine, 2013, Volume: 5, Issue:10

    Topics: Animals; Anti-Inflammatory Agents; Cell Line; Cell Membrane; Immunosuppressive Agents; Lasers; Mice;

2013
Fast walking velocity in health and Duchenne muscular dystrophy: a statistical analysis.
    Archives of physical medicine and rehabilitation, 1984, Volume: 65, Issue:10

    Topics: Adolescent; Adult; Age Factors; Braces; Child; Child, Preschool; Diethylstilbestrol; Female; Humans;

1984
[Value of the prednisolone test in myopathy diagnosis].
    Fortschritte der Neurologie-Psychiatrie, 1984, Volume: 52, Issue:1

    Topics: Adolescent; Adult; Creatine Kinase; Diagnosis, Differential; Female; Humans; Male; Middle Aged; Musc

1984
Clinical usefulness of urinary 3-methylhistidine excretion in indicating muscle protein breakdown.
    British medical journal (Clinical research ed.), 1981, Jan-31, Volume: 282, Issue:6261

    Topics: Adolescent; Adult; Aged; Child; Creatinine; Diabetes Mellitus; Diet; Female; Hip Joint; Histidine; H

1981
Failure of the prednisolone test in neuromuscular disorders.
    Italian journal of neurological sciences, 1982, Volume: 3, Issue:2

    Topics: Adolescent; Adult; Child; Clinical Enzyme Tests; Creatine Kinase; Humans; Middle Aged; Muscular Atro

1982
Decrease in urinary excretion of 3-methylhistidine by patients with Duchenne muscular dystrophy during glucocorticoid treatment.
    Journal of neurology, 1993, Volume: 240, Issue:3

    Topics: Adolescent; Child; Creatine Kinase; Glycine; Humans; Male; Methylhistidines; Muscles; Muscular Dystr

1993
47th ENMC International Workshop: Treatment of Muscular Dystrophy. 13-15 December 1996, Naarden, The Netherlands.
    Neuromuscular disorders : NMD, 1997, Volume: 7, Issue:4

    Topics: Anti-Inflammatory Agents; Humans; Muscular Dystrophies; Prednisolone; Pregnenediones

1997
[Effect of long-term administration of prednisolone on serum creatine kinase and muscle pathology of mdx mouse].
    Rinsho shinkeigaku = Clinical neurology, 1998, Volume: 38, Issue:8

    Topics: Animals; Anti-Inflammatory Agents; Creatine Kinase; Female; Male; Mice; Mice, Inbred mdx; Muscle, Sk

1998
Variable effects of corticosteroid treatment of serum enzyme activities in Duchenne's muscular dystrophy.
    Research communications in chemical pathology and pharmacology, 1977, Volume: 17, Issue:3

    Topics: Adolescent; Alkaline Phosphatase; Child; Creatine Kinase; Glucocorticoids; Humans; L-Lactate Dehydro

1977
Effects of the simultaneous administration of diethylstilbestrol and prednisolone on serum enzymes in Duchenne's muscular dystrophy.
    Journal of medicine, 1977, Volume: 8, Issue:2

    Topics: Child; Child, Preschool; Creatine Kinase; Diethylstilbestrol; Humans; L-Lactate Dehydrogenase; Male;

1977
Response of serum creatine phosphokinase to steroid hormone.
    Archives of neurology, 1975, Volume: 32, Issue:2

    Topics: Adolescent; Adult; Child; Child, Preschool; Creatine; Creatine Kinase; Creatinine; Diagnosis, Differ

1975
Nature of the mononuclear infiltrate and the mechanism of muscle damage in juvenile dermatomyositis and Duchenne muscular dystrophy.
    Journal of the neurological sciences, 1990, Volume: 99, Issue:2-3

    Topics: CD4-Positive T-Lymphocytes; Cells, Cultured; Dermatomyositis; HLA Antigens; Humans; Inflammation; In

1990
Ten years follow up study of steroid therapy for congenital encephalomyopathy.
    Brain & development, 1986, Volume: 8, Issue:3

    Topics: Azathioprine; Brain Diseases; Child; Child, Preschool; Creatine Kinase; Follow-Up Studies; Humans; I

1986
[Hormone therapy of muscular atrophy].
    Iryo, 1969, Volume: 23, Issue:10

    Topics: Adolescent; Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Anabolic Agents; Child; Creatine K

1969
Steroid-induced myopathy and diabetes. Report of a case.
    Oral surgery, oral medicine, and oral pathology, 1972, Volume: 33, Issue:4

    Topics: Aged; Diabetes Mellitus; Humans; Male; Mouth Diseases; Muscular Dystrophies; Pemphigus; Prednisolone

1972
Serum enzyme studies in acquired disease of skeletal muscle.
    Clinica chimica acta; international journal of clinical chemistry, 1971, Volume: 35, Issue:1

    Topics: Acyltransferases; Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Child; Creatine Ki

1971
[Experimental myopathies after treatment with prednisolone and thyroddrugs].
    Wiener klinische Wochenschrift, 1967, Apr-28, Volume: 79, Issue:17

    Topics: Adult; Animals; Body Weight; Child; Female; Humans; Muscle Proteins; Muscles; Muscular Diseases; Mus

1967